PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 15–15 | Cite as

Gefitinib, erlotinib preferred in EGFR-mutation+ NSCLC in China

Clinical study


  1. Cai H, et al. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer in China. Clinical Therapeutics : 11 Jan 2019. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations